相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M. Fischer et al.
CANCER DISCOVERY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Jeremie Nsengimana et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays
Sabah Kadri et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
Amanda D. Bucheit et al.
CLINICAL CANCER RESEARCH (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma
AC Peterson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
